Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01430299 · ClinicalTrials.gov registry record · NA

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

A NA study of Spondylosis and Stenosis, sponsored by SeaSpine.

Completed
Registry status
NA
Development phase
43
Enrollment target
1
Study location

NCT01430299: Completed NA study of Spondylosis and Stenosis, sponsored by SeaSpine.

NCT01430299 is a NA study of Spondylosis and Stenosis that has completed, run by SeaSpine. The registered enrollment target is 43 participants, below the 67-participant average among 8 other Spondylosis trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01430299, a NA study of Spondylosis and Stenosis, has completed, sponsored by SeaSpine.

COMPLETED
Registry status
NA
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.

Primary Outcome

Posterolateral fusion by radiographic assessment 12 months post surgery

Interventions

  • DEVICE Demineralized Bone Matrix
  • DEVICE rh-BMP2

Study Locations (1)

California

  • University of CA-Davis, Dept. of Orthopaedics, Adult & Pediatric Spine Surgery - Sacramento

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2011-06
Est. Completion 2016-10
Phase NA
SeaSpine

4 total trials

What the finished NCT01430299 record still lists

NCT01430299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 67-participant average among 8 other Spondylosis trials with a reported enrollment target (36% lower).

The record links to 3 conditions, with Spondylosis appearing as the primary indexed condition, and to 2 interventions - of which Demineralized Bone Matrix is the first listed.

NCT01430299 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01430299 about?

NCT01430299 is a clinical study titled "Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion". The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.

What is the current status of trial NCT01430299?

This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2011-06. Estimated completion is 2016-10.

What conditions does trial NCT01430299 study?

This clinical trial studies the following conditions: Spondylosis, Stenosis, Degenerative Changes.

What interventions are being tested in trial NCT01430299?

The interventions under investigation include: Demineralized Bone Matrix (DEVICE), rh-BMP2 (DEVICE).

Who is sponsoring clinical trial NCT01430299?

This trial is sponsored by SeaSpine, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01430299 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spondylosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01430299's enrollment target sits among peer trials

43 6th of 8 higher than 3 of 8 other Spondylosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Spondylosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01430299, the US trial registry maintained by the National Library of Medicine. NCT01430299 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.